好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Academic Underachievement is Common in Pediatric-Onset Multiple Sclerosis
Multiple Sclerosis
P4 - Poster Session 4 (8:00 AM-9:00 AM)
12-006

The aim of this study was to determine the rate of and characterize academic deficits in pediatric-onset multiple sclerosis (POMS) and compare these to cognitive deficits. 

Unlike with adult-onset MS, where a great deal is known about the effects of cognitive dysfunction on daily life, the functional impact in POMS is largely understudied.  

 

We administered a battery of neuropsychological tests and the Woodcock Test of Achievement (WCJ) to 23 participants with POMS and 11 healthy children (HC). Academic underachievement was defined as: (1) a z score of ≤ -1.5 standard deviation (SD) on the WCJ based on age-based normative data, and/or (2) a failing score on ≥ 2 statewide exams. Cognitive impairment was defined as: a score ≤ -1.5 SD on a total ≥ 1/3 of all cognitive tests administered, compared to age-based norms.  

11 of 23 POMS (48%) demonstrated academic underachievement compared to 1 of 11 HC (9%) (p=0.03). 8 of 23 POMS (35%) met criteria for cognitive impairment, compared to zero HC (p=0.03). POMS scored lower than HC on the WCJ Total Achievement Scale (x¯=93.2 vs x¯=112.6; p=0.0024, CI= [7.38, 31.4]). POMS with academic deficits were not more likely to have cognitive impairment than POMS without academic deficits (p=0.06). POMS had significantly lower scores than HC on the timed fluency section of the WCJ (x¯=88.3 vs. x¯=105.9, p=0.00122, CI=[7.50, 27.7] and on a timed section of the IQ test versus untimed sections (p=0.005, CI=[-15.8, 3.04]). 40% of POMS scored ≥ 1SD above their age and gender norms on a self-report depression scale, while zero HC scored in that range.

 

Children with MS demonstrate high levels of academic underachievement. Dedicated academic achievement testing should be part of the structured cognitive evaluation for children with MS. Extended time on tests may represent a crucial academic accommodation for this group. 

 

Authors/Disclosures
Wendy S. Vargas, MD (Sanofi)
PRESENTER
Dr. Vargas has received personal compensation for serving as an employee of Sanofi.
No disclosure on file
Hannah Z. Street Ms. Street has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Brenda L. Banwell, MD, FAAN (Johns Hopkins University) Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Philip De Jager, MD, PhD (Columbia University Irving Medical Center) Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from puretech.